Pharmesis to acquire remaining 19% stake in Sichuan Longlife Pharmaceutical

This agreement was finalised on 23 September.

Pharmesis International Ltd. has announced that its wholly-owned subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd., has signed a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharmaceutical Co., Ltd.

This agreement was finalised on 23 September.

The equity interest will be acquired from Chengdu Kinna Investment Co., Ltd., under the terms and conditions outlined in the SPA.

The acquisition is part of Pharmesis International's strategic efforts to enhance its portfolio and strengthen its position in the pharmaceutical industry.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia